Drug Profile
IDP 130
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Ortho Dermatologics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Acne in USA
- 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
- 13 Jan 2016 Clinical trials in Acne in USA (unspecified route) before January 2016